{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:26:52Z","timestamp":1756384012477,"version":"3.41.2"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T00:00:00Z","timestamp":1673308800000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Loss of response to anti-tumor necrosis factor drugs in patients with inflammatory bowel disease (IBD) is frequent and, in case of low drug levels, treatment intensification is recommended. In addition, in cases in which clinical response without attainment of remission (clinical, endoscopic, or radiological), intensification could be justified since higher drug levels are associated with better outcomes. For adalimumab (ADA), the standard intensification regimen is 40 mg every week (ew). Availability of ADA 80 mg prefilled pens has enabled every other week (eow) intensification. We assessed the clinical efficacy of intensification with ADA 80 mg eow.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective study was conducted at a tertiary hospital in Spain. Patients with IBD receiving maintenance ADA 80 mg eow with clinical, biomarker, and drug-level assessments were included. Demographics and clinical, biological, and endoscopic evaluation of the disease before and after ADA intensification, and pharmacokinetic assessments, were collected.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eighty-seven patients (72 Crohn\u2019s disease, 15 ulcerative colitis; average age 50 years) were included. Reasons for ADA intensification were: low ADA levels\u2014&amp;lt;5 \u00b5g mL\u22121\u2014(17%), low ADA levels\u2014&amp;lt;5 \u00b5g mL\u22121\u2014without clinical response (63%), clinical response without clinical remission (15%) and active disease on objective evaluation (including colonoscopy, magnetic resonance imaging, capsule endoscopy, and\/or intestinal ultrasound; 5%). Following treatment intensification to ADA 80 mg eow, 75 patients (86%) were in clinical remission and 69 (79.3%) were in biologic remission (clinical remission and normalization of biomarkers). After a median follow-up of 19 months (interquartile range 13\u201325), 63 patients (72%) remained on treatment and in clinical remission. There were no serious infections, hospitalizations, or deaths. Drug costs did not increase with the 80 mg eow regimen versus a standard intensification regimen.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>ADA intensification to 80 mg eow was safe, effective, and did not increase drug costs versus standard intensification to 40 mg ew in our experience.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/crocol\/otac051","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T20:11:36Z","timestamp":1673295096000},"source":"Crossref","is-referenced-by-count":3,"title":["Treatment With Adalimumab 80 mg Every Other Week in Inflammatory Bowel Disease: Results of Treatment Intensification in Clinical Practice"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0744-8636","authenticated-orcid":false,"given":"Marta","family":"Calvo Moya","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro Majadahonda , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yago","family":"Gonz\u00e1lez Lama","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro Majadahonda , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bel\u00e9n","family":"Ru\u00edz Antor\u00e1n","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department, Hospital Universitario Puerta de Hierro Majadahonda , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Omella Usieto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro Majadahonda , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismael","family":"el Hajra Martinez","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro Majadahonda , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Santos P\u00e9rez","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department, Hospital Universitario Puerta de Hierro Majadahonda , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bel\u00e9n","family":"Mench\u00e9n Viso","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy Service, Hospital Universitario Puerta de Hierro Majadahonda , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Matallana Royo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro Majadahonda , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Gonz\u00e1lez Partida","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro Majadahonda , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roc\u00edo","family":"de Lucas Tellez de Meneses","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro Majadahonda , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Bella Castillo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro Majadahonda , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Macarena","family":"Gonz\u00e1lez Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro Majadahonda , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Isabel","family":"Vera Mendoza","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro Majadahonda , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,1,10]]},"reference":[{"issue":"7","key":"2023021114514925200_CIT0001","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: Current management","volume":"11","author":"Harbord","year":"2017","journal-title":"J Crohns Colitis."},{"issue":"1","key":"2023021114514925200_CIT0002","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn\u2019s disease. Medical treatment","volume":"14","author":"Torres","year":"2019","journal-title":"J Crohns Colitis."},{"issue":"1","key":"2023021114514925200_CIT0003","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3748\/wjg.v20.i1.91","article-title":"Inflammatory bowel disease: pathogenesis","volume":"20","author":"Zhang","year":"2014","journal-title":"World J Gastroenterol."},{"issue":"4","key":"2023021114514925200_CIT0004","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/ajg.2011.103","article-title":"Assessing response and loss of response to biological therapies in IBD","volume":"106","author":"Yanai","year":"2011","journal-title":"Am J Gastroenterol."},{"issue":"9","key":"2023021114514925200_CIT0005","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Review article: loss of response to anti-TNF treatments in Crohn\u2019s disease","volume":"33","author":"Ben-Horin","year":"2011","journal-title":"Aliment Pharmacol Ther."},{"issue":"3","key":"2023021114514925200_CIT0006","first-page":"760","article-title":"Loss of response and requirement of infliximab dose intensification in Crohn\u2019s disease: a review","volume":"104","author":"Gisbert","year":"2009","journal-title":"Am J Gastroenterol."},{"key":"2023021114514925200_CIT0007","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12876-017-0654-1","article-title":"Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases.","volume":"17","author":"Gonczi","year":"2017","journal-title":"BMC Gastroenterol."},{"issue":"1","key":"2023021114514925200_CIT0008","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/apt.13445","article-title":"Systematic review: predicting and optimising response to anti-TNF therapy in Crohn\u2019s disease\u2014algorithm for practical management.","volume":"43","author":"Ding","year":"2016","journal-title":"Aliment Pharmacol Ther."},{"issue":"7","key":"2023021114514925200_CIT0009","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/17425255.2019.1630378","article-title":"Therapeutic drug monitoring to improve outcomes of anti-TNF drugs in pediatric inflammatory bowel disease.","volume":"15","author":"France","year":"2018","journal-title":"Exp Opin Drug Metab Toxicol."},{"issue":"1","key":"2023021114514925200_CIT0010","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000518755","article-title":"Proactive versus reactive therapeutic drug monitoring: why, when, and how?","volume":"7","author":"Shmais","year":"2022","journal-title":"Inflamm Intest Dis."},{"issue":"9","key":"2023021114514925200_CIT0011","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol."},{"issue":"5","key":"2023021114514925200_CIT0012","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology."},{"key":"2023021114514925200_CIT0013","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.dld.2016.11.002","article-title":"Adalimumab dose escalation is effective and well tolerated in Crohn\u2019s disease patients with secondary loss of response to adalimumab","volume":"49","author":"Duveau","year":"2017","journal-title":"Dig Liver Dis."},{"key":"2023021114514925200_CIT0014","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1007\/s10620-020-06567-x","article-title":"No difference of adalimumab pharmacokinetics when dosed 40 mg every week or 80 mg every other week in IBD patients in clinical remission after dose intensification","volume":"66","author":"Paul","year":"2021","journal-title":"Dig Dis Sci."},{"issue":"4","key":"2023021114514925200_CIT0015","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000486786","article-title":"Efficacy and safety of dose escalation to adalimumab 80 mg every other week in Japanese patients with Crohn\u2019s disease who lost response to maintenance therapy","volume":"2","author":"Motoya","year":"2018","journal-title":"Inflamm Intest Dis."},{"key":"2023021114514925200_CIT0016","first-page":"S390","article-title":"Efficacy, safety and cost-efficiency of adalimumab 80 mg every other week in previously intensified IBD patients under treatment with adalimumab 40 mg every week","volume-title":"J Crohn's Colitis.","author":"Ferreiro-Iglesias","year":"2019"},{"key":"2023021114514925200_CIT0017","article-title":"Efficacy, safety and cost-efficiency of adalimumab 80 mg every other week in previously intensified patients on adalimumab 40 mg every week","volume-title":"United European Gastroenterol J.","author":"Barreiro","year":"2019"},{"key":"2023021114514925200_CIT0018","first-page":"212","article-title":"La pauta de administraci\u00f3n de 80 mg cada dos semanas de Adalimumab se muestra no inferior a la de 40 mg semanal en pacientes con Enfermedad Inflamatoria Intestinal (EII)","volume-title":"SEPD.","author":"Fernandez-Perez","year":"2020"},{"key":"2023021114514925200_CIT0019","first-page":"S551","article-title":"Monitoring posologic change in adalimumab intensification dosing regimen from 40 mg every week to 80 mg every other week","volume-title":"J Crohn's Colitis.","author":"Diz Lois","year":"2020"},{"key":"2023021114514925200_CIT0020","article-title":"Comparison of serum adalimumab trough levels in 40 mg weekly vs 80 every two weeks intensification regimens in patients with inflammatory bowel disease","volume-title":"United European Gastroenterol J.","author":"Mart\u00edn-Arranz","year":"2020"},{"issue":"4","key":"2023021114514925200_CIT0021","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.cgh.2010.01.001","article-title":"Correlation between the Crohn\u2019s disease activity and Harvey-Bradshaw indices in assessing Crohn\u2019s disease severity","volume":"8","author":"Vermeire","year":"2010","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2023021114514925200_CIT0022","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/apt.15643","article-title":"Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease","volume":"51","author":"Gibson","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"key":"2023021114514925200_CIT0023","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.gastro.2017.07.031","article-title":"American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases.","volume":"153","author":"Vande Casteele","year":"2017","journal-title":"Gastroenterology."},{"issue":"9","key":"2023021114514925200_CIT0024","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.cgh.2019.03.037","article-title":"Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases","volume":"17","author":"Papamichael","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"4","key":"2023021114514925200_CIT0025","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.cgh.2015.10.025","article-title":"Optimizing anti-TNF-a therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases","volume":"14","author":"Ungar","year":"2016","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"11","key":"2023021114514925200_CIT0026","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1097\/MIB.0000000000001223","article-title":"Distinct thresholds of infliximab trough level are associated with different therapeutic outcomes in patients with inflammatory bowel disease: a prospective observational study","volume":"23","author":"Roblin","year":"2017","journal-title":"Inflamm Bowel Dis."},{"issue":"1-2","key":"2023021114514925200_CIT0027","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000443135","article-title":"The future of IBD therapy: where are we and where should we go next?","volume":"34","author":"Mao","year":"2016","journal-title":"Dif Dis."},{"issue":"4","key":"2023021114514925200_CIT0028","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s11894-014-0378-0","article-title":"Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives","volume":"16","author":"Vande Casteele","year":"2014","journal-title":"Curr Gastroenterol Rep."},{"issue":"1","key":"2023021114514925200_CIT0029","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.dld.2021.06.005","article-title":"Treatment patterns and intensification within 5 years of follow-up of the first-line anti-TNF-\u03b1 used for the treatment of IBD: results from the VERNE study.","volume":"54","author":"Bastida","year":"2022","journal-title":"Dig Liver Dis."},{"issue":"5","key":"2023021114514925200_CIT0030","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/ecco-jcc\/jjw002","article-title":"Non-adherence to anti-TNF therapy is associated with illness perceptions and clinical outcomes in outpatients with inflammatory bowel disease: results from a prospective multicentre study","volume":"10","author":"Van der HaveJansen","year":"2016","journal-title":"J Crohns Colitis."},{"issue":"5","key":"2023021114514925200_CIT0031","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti-TNF treatment failure in anti-TNF-na\u00efve patients with active luminal Crohn\u2019s disease: a prospective, multicentre, cohort study.","volume":"4","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"24","key":"2023021114514925200_CIT0032","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/MIB.0000000000001043","article-title":"A real-life population pharmacokinetic study reveals factors associated with clearance and immunogenicity of infliximab in inflammatory bowel disease.","volume":"23","author":"Brandse","year":"2017","journal-title":"Inflamm Bowel Dis."},{"issue":"3","key":"2023021114514925200_CIT0033","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.cgh.2014.07.029","article-title":"Levels of drug and antidrug antibodies are associated with outcome on interventions after loss of response to infliximab or adalimumab.","volume":"13","author":"Yanai","year":"2015","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"9","key":"2023021114514925200_CIT0034","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3748\/wjg.v28.i9.961","article-title":"Relationship between clinical remission of perianal fistulas in Crohn\u2019s disease and serum adalimumab concentrations: a multicenter cross-sectional study.","volume":"28","author":"Sirmai","year":"2022","journal-title":"World J Gastroenterol."},{"key":"2023021114514925200_CIT0035","first-page":"1","article-title":"Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study.","volume":"4","author":"Taxonera","year":"2021","journal-title":"Ther Adv Gastroenterol."}],"container-title":["Crohn's &amp; Colitis 360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/advance-article-pdf\/doi\/10.1093\/crocol\/otac051\/48592699\/otac051.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/5\/1\/otac051\/49160717\/otac051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article-pdf\/5\/1\/otac051\/49160717\/otac051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T14:52:20Z","timestamp":1676127140000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/crohnscolitis360\/article\/doi\/10.1093\/crocol\/otac051\/6981279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/crocol\/otac051","relation":{},"ISSN":["2631-827X"],"issn-type":[{"type":"electronic","value":"2631-827X"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2023,1,1]]},"article-number":"otac051"}}